Meropenem Kabi (Meropenem Trihydrate)

Meropenem inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins. This blocks the cross‑linking of peptidoglycan strands, weakening the cell wall and causing bacterial lysis and death. Its high affinity for a wide range of PBPs gives it activity against many resistant organisms.

The specific dose of Meropenem Kabi is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. Healthcare professionals tailor the regimen to each individual case.

Safety data for meropenem in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should evaluate each case carefully and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the Meropenem Kabi product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and required import documentation.

Meropenem Kabi shares the broad‑spectrum activity typical of carbapenems but offers a stable formulation suitable for intravenous infusion. Compared with imipenem‑cilastatin, meropenem has a lower risk of nephrotoxicity and does not require co‑administration with a renal dehydropeptidase inhibitor. Choice of agent depends on local resistance patterns and patient‑specific factors.

Meropenem Kabi should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside this range.

Meropenem Kabi is given as an intravenous infusion. The infusion rate and duration are set by the prescribing clinician, typically over 15‑30 minutes, and may be adjusted based on patient tolerance and renal function. Administration should follow aseptic technique in a clinical setting.

Serious risks include anaphylactic reactions, seizures (especially in patients with renal impairment or pre‑existing CNS disorders), Clostridioides difficile‑associated colitis, and severe thrombocytopenia. Prompt recognition and medical intervention are essential if any of these events occur.

Patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation should not receive Meropenem Kabi. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those taking medications that may interact significantly, such as valproic acid.